Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars

'This is important for our own pharmacovigilance,' US FDA commissioner says. 'We still have an open question on whether or not we’re going to apply a suffix or change also the branded company’s name as well.'

the word suffix on cubes

The US FDA’s guidance on biologics and biosimilar naming has been final for 18 months, but the agency continues to face implementation challenges as well as hear worries from stakeholders.

Commissioner Scott Gottlieb was asked during a July 18 address at the Brookings Institution to unveil the agency’s Biosimilar...

More from Biosimilars

More from Biosimilars & Generics